Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 345

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Prostate-Only Versus Whole-Pelvic Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer (POP-RT): Outcomes From Phase III Randomized Controlled Trial

Murthy, Vedang, Maitre, Priyamvada, Kannan, Sadhana, Panigrahi, Gitanjali, Krishnatry, Rahul, Bakshi, Ganesh, Prakash, Gagan, Pal, Mahendra, Menon, Santosh, Phurailatpam, Reena, Mokal, Smruti, Chaurasiya, Dipika, Popat, Palak, Sable, Nilesh, Agarwal, Archi, Rangarajan, Venkatesh, Joshi, Amit, Noronha, Vanita, Prabhash, Kumar, Mahantshetty, Umesh · 2021 · Journal of Clinical Oncology

Abstract

PURPOSE: We report the clinical outcomes of a randomized trial comparing prophylactic whole-pelvic nodal radiotherapy to prostate-only radiotherapy (PORT) in high-risk prostate cancer. METHODS: This phase III, single center, randomized controlled trial enrolled eligible patients undergoing radical radiotherapy for node-negative prostate adenocarcinoma, with estimated nodal risk ≥ 20%. Randomization was 1:1 to PORT (68 Gy/25# to prostate) or whole-pelvic radiotherapy (WPRT, 68 Gy/25# to prostate, 50 Gy/25# to pelvic nodes, including common iliac) using computerized stratified block randomization, stratified by Gleason score, type of androgen deprivation, prostate-specific antigen at diagnosis, and prior transurethral resection of the prostate. All patients received image-guided, intensity-modulated radiotherapy and minimum 2 years of androgen deprivation therapy. The primary end point was 5-year biochemical failure-free survival (BFFS), and secondary end points were disease-free survival (DFS) and overall survival (OS). RESULTS: From November 2011 to August 2017, a total of 224 patients were randomly assigned (PORT = 114, WPRT = 110). At a median follow-up of 68 months, 36 biochemical failures (PORT = 25, WPRT = 7) and 24 deaths (PORT = 13, WPRT = 11) were recorded. Five-year BFFS was 95.0% (95% CI, 88.4 to 97.9) with WPRT versus 81.2% (95% CI, 71.6 to 87.8) with PORT, with an unadjusted hazard ratio (HR) of 0.23 (95% CI, 0.10 to 0.52; P < .0001). WPRT also showed higher 5-year DFS (89.5% v 77.2%; HR, 0.40; 95% CI, 0.22 to 0.73; P = .002), but 5-year OS did not appear to differ (92.5% v 90.8%; HR, 0.92; 95% CI, 0.41 to 2.05; P = .83). Distant metastasis-free survival was also higher with WPRT (95.9% v 89.2%; HR, 0.35; 95% CI, 0.15 to 0.82; P = .01). Benefit in BFFS and DFS was maintained across prognostic subgroups. CONCLUSION: Prophylactic pelvic irradiation for high-risk, locally advanced prostate cancer improved BFFS and DFS as compared with PORT, but OS did not appear to differ.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.20.03282

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Cited by

See all 345

Metadata

Authors
Murthy, V., Maitre, P., Kannan, S., Panigrahi, G., Krishnatry, R., Bakshi, G., Prakash, G., Pal, M., Menon, S., Phurailatpam, R., Mokal, S., Chaurasiya, D., Popat, P., Sable, N., Agarwal, A., Rangarajan, V., Joshi, A., Noronha, V., Prabhash, K., & Mahantshetty, U.
Venue
Journal of Clinical Oncology
Published
2021-04-10
Volume
39
Issue
11
Pages
1234-1242
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W3125743225
Cited by
345
References
15
FWCI
33.90
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Prostate-Only Versus Whole-Pelvic Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer (POP-RT): Outcomes From Phase III Randomized Controlled Trial. https://app.cochat.ai/papers/10.1200/jco.20.03282
The paper
Murthy, V., Maitre, P., Kannan, S., Panigrahi, G., Krishnatry, R., Bakshi, G., Prakash, G., Pal, M., Menon, S., Phurailatpam, R., Mokal, S., Chaurasiya, D., Popat, P., Sable, N., Agarwal, A., Rangarajan, V., Joshi, A., Noronha, V., Prabhash, K., & Mahantshetty, U. (2021). Prostate-Only Versus Whole-Pelvic Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer (POP-RT): Outcomes From Phase III Randomized Controlled Trial. Journal of Clinical Oncology. https://doi.org/10.1200/jco.20.03282

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.